



	Dr. Vinay Chopra MD (Pathology & Microbiolog Chairman & Consultant Patho	gy)	Yugam Chop MD (Patholog onsultant Patholog	gy)
AGE/ GENDER: 54 YRS/FICOLLECTED BY: SURJESHREFERRED BY: CENTRALBARCODE NO.: 01521296CLIENT CODE.: KOS DIAG	PHOENIX CLUB (AMBALA CAN	COLLECTION DA REPORTING DAT	DATE : 23/N TE : 23/N	9891 411230022 Nov/2024 09:56 AM Nov/2024 09:57AM Nov/2024 10:10AM
Test Name	Value	e Ľ	Jnit	Biological Reference interval
RED BLOOD CELLS (RBCS) CO	COMPLETI	WELLNESS PAN E BLOOD COUNT (
HAEMOGLOBIN (HB)	12.4	e e	gm/dL	12.0 - 16.0
RED BLOOD CELL (RBC) COUN		s N	Millions/cmm	3.50 - 5.00
by HYDRO DYNAMIC FOCUSING, ELE PACKED CELL VOLUME (PCV)	39.7	, <u> </u>	%	37.0 - 50.0
by CALCULATED BY AUTOMATED HE MEAN CORPUSCULAR VOLUME	(MCV) 86.7	ŕ	L	80.0 - 100.0
by CALCULATED BY AUTOMATED HE MEAN CORPUSCULAR HAEMOO by CALCULATED BY AUTOMATED HE	GLOBIN (MCH) 27.1	. F	og	27.0 - 34.0
MEAN CORPUSCULAR HEMOGI by CALCULATED BY AUTOMATED HE	LOBIN CONC. (MCHC) 31.3	j L g	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WID'	TH (RDW-CV) 13.6	9	%	11.00 - 16.00
RED CELL DISTRIBUTION WID by CALCULATED BY AUTOMATED HI	TH (RDW-SD) 44.1	f	L	35.0 - 56.0
MENTZERS INDEX by CALCULATED	18.9	13 F	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by calculated WHITE BLOOD CELLS (WBCS)	25.7	7	RATIO	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
TOTAL LEUCOCYTE COUNT (TI by FLOW CYTOMETRY BY SF CUBE &	.C) 485	0 /	′cmm	4000 - 11000
NUCLEATED RED BLOOD CELL by AUTOMATED 6 PART HEMATOLO	S (nRBCS) NIL			0.00 - 20.00
NUCLEATED RED BLOOD CELL		9	%	< 10 %





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







Dr. Yugam Chopra

MD (Pathology & Microbiology) MD (Pathology) Chairman & Consultant Pathologist **CEO & Consultant Pathologist** NAME : Mrs. HARPREET KAUR **AGE/ GENDER** : 54 YRS/FEMALE **PATIENT ID** :1679891 **COLLECTED BY** : SURJESH :012411230022 REG. NO./LAB NO. **REFERRED BY** : CENTRAL PHOENIX CLUB (AMBALA CANTT) **REGISTRATION DATE** : 23/Nov/2024 09:56 AM **BARCODE NO.** :01521296 **COLLECTION DATE** : 23/Nov/2024 09:57AM CLIENT CODE. : KOS DIAGNOSTIC LAB **REPORTING DATE** : 23/Nov/2024 10:10AM **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT Test Name Value Unit **Biological Reference interval DIFFERENTIAL LEUCOCYTE COUNT (DLC) NEUTROPHILS** 52 % 50 - 70 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY LYMPHOCYTES 36 % 20 - 40 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY EOSINOPHILS 4 % 1 - 6 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY MONOCYTES 8 % 2 - 12by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY BASOPHILS 0 % 0 - 1 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY **ABSOLUTE LEUKOCYTES (WBC) COUNT** ABSOLUTE NEUTROPHIL COUNT 2522 2000 - 7500 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE LYMPHOCYTE COUNT 1746 800 - 4900 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE EOSINOPHIL COUNT 194 /cmm 40 - 440 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE MONOCYTE COUNT 388 /cmm 80 - 880 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE BASOPHIL COUNT 0 /cmm 0 - 110 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY PLATELETS AND OTHER PLATELET PREDICTIVE MARKERS. PLATELET COUNT (PLT) 150000 - 450000 217000 /cmm by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELETCRIT (PCT) 0.26 % 0.10 - 0.36 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE MEAN PLATELET VOLUME (MPV) fL 12 6.50 - 12.0 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE 30000 - 90000 PLATELET LARGE CELL COUNT (P-LCC) 87000 /cmm by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE % PLATELET LARGE CELL RATIO (P-LCR) 4011.0 - 45.0 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELET DISTRIBUTION WIDTH (PDW) 15.0 - 17.0 16.3% by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD

Dr. Vinay Chopra

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 2 of 20





Test Name	Value	Unit	Biological Reference interval
CLIENT ADDRESS	. 0549/1, NICHOLSON KOAD, AMBALA CANTT		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Nov/2024 10:10AM
BARCODE NO.	: 01521296	COLLECTION DATE	: 23/Nov/2024 09:57AM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230022
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891
NAME	: Mrs. HARPREET KAUR		
	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist		(Pathology)



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Cho MD (Pathology & Chairman & Cons	Microbiology)	Dr. Yugan MD CEO & Consultant	(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE	P	PATIENT ID	: 1679891
COLLECTED BY	: SURJESH	R	REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AM	(IBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296		COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	R	REPORTING DATE	: 23/Nov/2024 03:11PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT		
Test Name		Value	Unit	Biological Reference interva
WHOLE BLOOD	GLYCO EMOGLOBIN (HbA1c): <i>RMANCE LIQUID CHROMATOGRAPHY</i>)	DSYLATED HAH 5.7	EMOGLOBIN (HBA1) %	C) 4.0 - 6.4
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA	EMOGLOBIN (HbA1c):			
WHOLE BLOOD by HPLC (HIGH PERFOI ESTIMATED AVERA by HPLC (HIGH PERFOI	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	5.7 116.89	% mg/dL	4.0 - 6.4
WHOLE BLOOD by HPLC (HIGH PERFOI ESTIMATED AVERA by HPLC (HIGH PERFOI INTERPRETATION:	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE	5.7 116.89 DIABETES ASSOCIAT	% mg/dL	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFOI ESTIMATED AVERA by HPLC (HIGH PERFOI INTERPRETATION:	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I	5.7 116.89 DIABETES ASSOCIAT	% mg/dL TION (ADA):	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFON ESTIMATED AVERA by HPLC (HIGH PERFON INTERPRETATION: NON dia A	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes)	5.7 116.89 DIABETES ASSOCIAT	% mg/dL TION (ADA): COSYLATED HEMOGLOGIB <5.7 5.7 - 6.4	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFON ESTIMATED AVERA by HPLC (HIGH PERFON INTERPRETATION: NON dia A	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years	5.7 116.89 DIABETES ASSOCIAT	% mg/dL TION (ADA): COSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFON ESTIMATED AVERA by HPLC (HIGH PERFON INTERPRETATION: Non dia A D	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes)	5.7 116.89 DIABETES ASSOCIAT GLY Goals o	% mg/dL TION (ADA): COSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years if Therapy:	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFON ESTIMATED AVERA by HPLC (HIGH PERFON INTERPRETATION: Non dia A D	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes) iagnosing Diabetes	5.7 116.89 DIABETES ASSOCIAT GLY Goals o	% mg/dL TION (ADA): COSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years	4.0 - 6.4 60.00 - 140.00 (HBAIC) in % < 7.0

COMMENTS:

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 4 of 20





Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist			(Pathology)		
NAME	: Mrs. HARPR	EET KAUR			
AGE/ GENDER	: 54 YRS/FEMA	ALE		PATIENT ID	: 1679891
COLLECTED BY	: SURJESH			REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PH	OENIX CLUB (AM	IBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	:01521296			COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNO	STIC LAB		REPORTING DATE	: 23/Nov/2024 10:20AM
CLIENT ADDRESS	: 6349/1, NICH	HOLSON ROAD, A	MBALA CANTT		
Test Name			Value	Unit	Biological Reference interva
		FRYTHR	OCYTE SEDI	MENTATION RATE (H	(SR)
2. An ESR can be affe as C-reactive protein 3. This test may also systemic lupus erythe CONDITION WITH LOV	cted by other con be used to monit ematosus V ESR n with condition:	nditions besides i for disease activit	nflammation. Fo y and response normal sedimen	to therapy in both of the ak	body of what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count

KOS Diagnostic Lab (A Unit of KOS Healthcare)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chopra MD (Pathology & Micro Chairman & Consultant		Dr. Yugam C MD (Pai EO & Consultant Pat	thology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT	'ID :	1679891
COLLECTED BY	: SURJESH	REG. NO.	/LAB NO. :	012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBAL	A CANTT) REGISTR	ATION DATE :	23/Nov/2024 09:56 AM
BARCODE NO.	:01521296	COLLECT	TON DATE :	23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORT	ING DATE :	23/Nov/2024 11:01AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBA	LA CANTT		
Test Name		Value	Unit	Biological Reference interval
		HEMISTRY/B		Ϋ́
	G	LUCOSE FASTIN	G (F)	
GLUCOSE FASTIN	G (F): PLASMA SE - PEROXIDASE (GOD-POD)	97.17	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0

KOS Diagnostic Lab (A Unit of KOS Healthcare)

A fasting plasma glucose level below 100 mg/dl is considered normal.
 A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood

test (after consumption of 75 gms of glucose) is recommended for all such patients. 3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







		hopra & Microbiology) nsultant Pathologis		(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE		PATIENT ID	: 1679891
COLLECTED BY	: SURJESH		REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	:01521296		COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD), AMBALA CANTT		
Fest Name		Value	Unit	Biological Reference interval
		LIPID PR	OFILE : BASIC	
HOLESTEROL TO	TAL · SFRUM	214.78 ^H	mg/dL	OPTIMAL: < 200.0
by CHOLESTEROL OX		214./8 ^m	iiig/ uL	BORDERLINE HIGH: 200.0 -
				239.0
				HIGH CHOLESTEROL: > OR = 240.0
RIGLYCERIDES: S		146.36	mg/dL	OPTIMAL: < 150.0
by GLYCEROL PHOSP	PHATE OXIDASE (ENZYMATIC)			BORDERLINE HIGH: 150.0 - 199.0
				HIGH: 200.0 - 499.0
				VERY HIGH: $> OR = 500.0$
IDL CHOLESTERO	L (DIRECT): SERUM	59.86	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0
Sy CLECTIVE WWW.DM				60.0
				HIGH HDL: $> OR = 60.0$
DL CHOLESTEROI by CALCULATED, SPE		125.65	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.
				BORDERLINE HIGH: 130.0 -
				159.0 HIGH: 100.0 190.0
				HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLEST		154.92 ^H	mg/dL	OPTIMAL: < 130.0
by CALCULATED, SPE	CTROPHOTOMETRY			ABOVE OPTIMAL: 130.0 - 159. BORDERLINE HIGH: 160.0 -
				189.0
				HIGH: 190.0 - 219.0
VLDL CHOLESTER	OI · SERUM	29.27	mg/dL	VERY HIGH: > OR = 220.0 0.00 - 45.00
by CALCULATED, SPE	CTROPHOTOMETRY			
FOTAL LIPIDS: SER by calculated, spe		575.92	mg/dL	350.00 - 700.00
CHOLESTEROL/HD	DL RATIO: SERUM	3.59	RATIO	LOW RISK: 3.30 - 4.40
by CALCULATED, SPE	CTROPHOTOMETRY			AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0



an

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab:6349/1, Nicholson Road, Ambala Cantt -133 001, HaryanaKOS Molecular Lab:IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana0171-2643898, +91 99910 43898care@koshealthcare.comwww.koshealthcare.comwww.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologi		(Pathology)
NAME	: Mrs. HARPREET KAUR		
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296	COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT	Г	
Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: S by CALCULATED, SPE		RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/H by CALCULATED, SPE	IDL RATIO: SERUM 2.45^L	RATIO	3.00 - 5.00

INTERPRETATION: 1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chop MD (Pathology & Mid Chairman & Consulta	crobiology)		(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE		PATIENT ID	: 1679891
COLLECTED BY	: SURJESH		REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBA	ALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296		COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMI	BALA CANTT	2	
Test Name		Value	Unit	Biological Reference interval
BILIRUBIN DIRECT by DIAZO MODIFIED, S BILIRUBIN INDIRE	: SERUM PECTROPHOTOMETRY Γ (CONJUGATED): SERUM SPECTROPHOTOMETRY CCT (UNCONJUGATED): SERUM	FUNCTIO 0.74 0.14 0.6	N TEST (COMPLETE) mg/dL mg/dL mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20 0.00 - 0.40 0.10 - 1.00
by CALCULATED, SPE SGOT/AST: SERUM	[23.95	U/L	7.00 - 45.00
SGPT/ALT: SERUM	/RIDOXAL PHOSPHATE [/RIDOXAL PHOSPHATE	24.34	U/L	0.00 - 49.00
AST/ALT RATIO: S	ERUM	0.98	RATIO	0.00 - 46.00
ALKALINE PHOSPI by PARA NITROPHEN PROPANOL	HATASE: SERUM YL PHOSPHATASE BY AMINO METHYL	111.51	U/L	40.0 - 130.0
GAMMA GLUTAMY by SZASZ, SPECTRO	L TRANSFERASE (GGT): SERUM	17.68	U/L	0.00 - 55.0
TOTAL PROTEINS: by BIURET, SPECTRO		7.43	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL G		4.2	gm/dL	3.50 - 5.50
GLOBULIN: SERUN by CALCULATED, SPE		3.23	gm/dL	2.30 - 3.50
A : G RATIO: SERUI		1.3	RATIO	1.00 - 2.00

by CALCULATED, SPECTROPHOTOMETRY

INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

USE:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologis		(Pathology)
NAME	: Mrs. HARPREET KAUR		
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296	COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT	2	
Test Name	Value	Unit	Biological Reference interval

DECREASED:

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Cho MD (Pathology & M Chairman & Consu	1icrobiology)		(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE		PATIENT ID	: 1679891
COLLECTED BY	: SURJESH		REG. NO./LAB NO.	:012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AM	BALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	:01521296		COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT		
Test Name		Value	Unit	Biological Reference interva
	KIDNI	EY FUNCTIO	N TEST (COMPLETE)	
UREA: SERUM		20.99	mg/dL	10.00 - 50.00
by UREASE - GLUTAN CREATININE: SERI	MATE DEHYDROGENASE (GLDH)	0.9	mg/dI	0.40 - 1.20
by ENZYMATIC, SPEC		0.9	mg/dL	0.40 - 1.20
	ROGEN (BUN): SERUM	9.81	mg/dL	7.0 - 25.0
by CALCULATED, SPE BLOOD UREA NITE	ROGEN (BUN)/CREATININE	10.9	RATIO	10.0 - 20.0
RATIO: SERUM				
by CALCULATED, SPE UREA/CREATININ		23.32	RATIO	
by CALCULATED, SPE		20.02	RAHO	
URIC ACID: SERUM by URICASE - OXIDAS		4.3	mg/dL	2.50 - 6.80
CALCIUM: SERUM	SEPEROXIDASE	9.74	mg/dL	8.50 - 10.60
by ARSENAZO III, SPE			-	
PHOSPHOROUS: SE by PHOSPHOMOLYBE	CKUM DATE, SPECTROPHOTOMETRY	3.29	mg/dL	2.30 - 4.70
ELECTROLYTES				
SODIUM: SERUM		141.5	mmol/L	135.0 - 150.0
by ISE (ION SELECTIV POTASSIUM: SERU		4.18	mmol/L	3.50 - 5.00
by ISE (ION SELECTIV	/E ELECTRODE)			
CHLORIDE: SERUN by ISE (ION SELECTIV		106.13	mmol/L	90.0 - 110.0
	IERULAR FILTERATION RATE			
ESTIMATED GLOM	ERULAR FILTERATION RATE	76		
(eGFR): SERUM by CALCULATED				
INTERPRETATION:				
In dittorantiata botw	oon nro, and nost ronal azotomia			

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE: 1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

2. Catabolic states with increased tissue breakdown.

3. GI haemorrhage.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Micro Chairman & Consultant	biology)	Yugam Chopra MD (Pathology) Isultant Pathologist	
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891	
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230	199
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA			
BARCODE NO.	: 01521296	COLLECTION DAT	E : 23/Nov/2024	09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATI	E : 23/Nov/2024	11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBA	LA CANTT		
Test Name		Value Un	it Biolo	gical Reference interval
8. Reduced muscle m 9. Certain drugs (e.g. INCREASED RATIO (>2	xia, high fever). (e.g. ureter colostomy) ass (subnormal creatinine production) tetracycline, glucocorticoids) 0:1) WITH ELEVATED CREATININE LEVEL (BUN rises disproportionately more th		e uropathy).	
8. Reduced muscle m 9. Certain drugs (e.g. INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (<1 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome c 8. Pregnancy. DECREASED RATIO (<1 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther	(e.g. ureter colostomy) ass (subnormal creatinine production) tetracycline, glucocorticoids) 0:1) WITH ELEVATED CREATININE LEVEL (BUN rises disproportionately more th superimposed on renal disease. 0:1) WITH DECREASED BUN : osis. d starvation. 2. creased urea synthesis. urea rather than creatinine diffuses ou monemias (urea is virtually absent in b f inappropiate antidiuretic harmone) d 0:1) WITH INCREASED CREATININE: py (accelerates conversion of creatine eleases muscle creatinine). who develop renal failure. : sis (acetoacetate causes false increase creased BUN/creatinine ratio). apy (interferes with creatinine measure LAR FILTERATION RATE: DESCRIPTION Normal kidney function Kidney damage with	an creatinine) (e.g. obstructive it of extracellular fluid). ilood). ue to tubular secretion of urea to creatinine). in creatinine with certain met	hodologies,resulting in n ASSOCIATED FINDING No proteinuria Presence of Protein	IS
8. Reduced muscle m 9. Certain drugs (e.g. INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (<1 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome c 8. Pregnancy. DECREASED RATIO (<1 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERL CKD STAGE G1 G2	(e.g. ureter colostomy) ass (subnormal creatinine production) tetracycline, glucocorticoids) 0:1) WITH ELEVATED CREATININE LEVEL (BUN rises disproportionately more th superimposed on renal disease. 0:1) WITH DECREASED BUN : osis. d starvation. 2. creased urea synthesis. urea rather than creatinine diffuses ou monemias (urea is virtually absent in b f inappropiate antidiuretic harmone) d 0:1) WITH INCREASED CREATININE: py (accelerates conversion of creatine eleases muscle creatinine). who develop renal failure. : sis (acetoacetate causes false increase creased BUN/creatinine ratio). apy (interferes with creatinine measure LAR FILTERATION RATE: DESCRIPTION Normal kidney function Kidney damage with normal or high GFR	an creatinine) (e.g. obstructive at of extracellular fluid). lood). ue to tubular secretion of urea to creatinine). in creatinine with certain met ement). GFR (mL/min/1.73m2) >90 >90	hodologies,resulting in n ASSOCIATED FINDING No proteinuria	IS
8. Reduced muscle m 9. Certain drugs (e.g. INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (<1 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome c 8. Pregnancy. DECREASED RATIO (<1 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERL G1 G2 G3a	(e.g. ureter colostomy) ass (subnormal creatinine production) tetracycline, glucocorticoids) 0:1) WITH ELEVATED CREATININE LEVEL (BUN rises disproportionately more th superimposed on renal disease. 0:1) WITH DECREASED BUN : osis. d starvation. 2. creased urea synthesis. urea rather than creatinine diffuses ou monemias (urea is virtually absent in b f inappropiate antidiuretic harmone) d 0:1) WITH INCREASED CREATININE: py (accelerates conversion of creatine eleases muscle creatinine). who develop renal failure. : sis (acetoacetate causes false increase creased BUN/creatinine ratio). apy (interferes with creatinine measure LAR FILTERATION RATE: DESCRIPTION Normal kidney function Kidney damage with normal or high GFR Mild decrease in GFR	an creatinine) (e.g. obstructive of extracellular fluid). Nood). ue to tubular secretion of urea to creatinine). in creatinine with certain met ement). GFR (mL/min/1.73m2) >90 >90 60 -89	hodologies,resulting in n ASSOCIATED FINDING No proteinuria Presence of Protein	IS
8. Reduced muscle m 9. Certain drugs (e.g. INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (<1 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome c 8. Pregnancy. DECREASED RATIO (<1 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERU G1 G2	(e.g. ureter colostomy) ass (subnormal creatinine production) tetracycline, glucocorticoids) 0:1) WITH ELEVATED CREATININE LEVEL (BUN rises disproportionately more th superimposed on renal disease. 0:1) WITH DECREASED BUN : osis. d starvation. 2. creased urea synthesis. urea rather than creatinine diffuses ou monemias (urea is virtually absent in b f inappropiate antidiuretic harmone) d 0:1) WITH INCREASED CREATININE: py (accelerates conversion of creatine eleases muscle creatinine). who develop renal failure. : sis (acetoacetate causes false increase creased BUN/creatinine ratio). apy (interferes with creatinine measure LAR FILTERATION RATE: DESCRIPTION Normal kidney function Kidney damage with normal or high GFR	an creatinine) (e.g. obstructive at of extracellular fluid). lood). ue to tubular secretion of urea to creatinine). in creatinine with certain met ement). GFR (mL/min/1.73m2) >90 >90	hodologies,resulting in n ASSOCIATED FINDING No proteinuria Presence of Protein	IS



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologis		(Pathology)
NAME	: Mrs. HARPREET KAUR		
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296	COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT	ſ	
Test Name	Value	Unit	Biological Reference interval

COMMENTS:

Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.
 eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012
 In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure of CFD with the commended to measure

3. In patients, with eGFR cleaning between 45-59 minimit 1.73 m2 (G3) and without any marker of Kidney damage, it is recommended to measure eGFR with Cystatin C for confirmation of CKD
4. eGFR category G1 OR G2 does not fulfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chop MD (Pathology & Mi Chairman & Consult	crobiology)		(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE		PATIENT ID	: 1679891
COLLECTED BY	: SURJESH		REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMB	ALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296		COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 23/Nov/2024 11:24AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AM	BALA CANTT	,	
Test Name		Value	Unit	Biological Reference interval
		IRON	PROFILE	
IRON: SERUM by ferrozine, spect	TROPHOTOMETRY	64.2	μg/dL	37.0 - 145.0
UNSATURATED IRC SERUM by FERROZINE, SPECT	ON BINDING CAPACITY (UIBC)	225.78	µg/dL	150.0 - 336.0
	NG CAPACITY (TIBC)	289.98	µg/dL	230 - 430
%TRANSFERRIN SA	ATURATION: SERUM CTROPHOTOMETERY (FERENE)	22.14	%	15.0 - 50.0
TRANSFERRIN: SEI	RUM	205.89	mg/dL	200.0 - 350.0
INTERPRETATION:- VARIAB	IES ANEMIA OF CHRO		IRON DEFICIENCY ANEMI	A THALASSEMIA α/β TRAIT

VARIABLES	ANEMIA OF CHRONIC DISEASE	IRON DEFICIENCY ANEMIA	THALASSEMIA α/β TRAIT
SERUM IRON:	Normal to Reduced	Reduced	Normal
TOTAL IRON BINDING CAPACITY:	Decreased	Increased	Normal
% TRANSFERRIN SATURATION:	Decreased	Decreased < 12-15 %	Normal
SERUM FERRITIN:	Normal to Increased	Decreased	Normal or Increased
IDON.			

IRON:

1.Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency

anemia, anemia of chronic disease and thalassemia syndromes.
 It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.
 TOTAL IRON BINDING CAPACITY (TIBC): It is a direct measure of protein transferrin which transports iron from the gut to storage sites in the bone marrow.

% TRANSFERRIN SATURATION:

1. Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Microbio Chairman & Consultant Pa		Dr. Yugam MD (CEO & Consultant	(Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE	PA	TIENT ID	: 1679891
COLLECTED BY	: SURJESH	RE	G. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA C	ANTT) Re	GISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	:01521296	CO	LLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RE	PORTING DATE	: 23/Nov/2024 12:29PM
Test Name	Val	lue	Unit	Biological Reference interval
	EN	IDOCDI		
			NOLOGY DN TEST: TOTAL	
	THYROID			0.35 - 1.93
by CMIA (CHEMILUMIN THYROXINE (T4): S	THYROID NE (T3): SERUM IESCENT MICROPARTICLE IMMUNOASSAY)	FUNCTIO 781	ON TEST: TOTAL	0.35 - 1.93 4.87 - 12.60
by CMIA (CHEMILUMIN THYROXINE (T4): 5 by CMIA (CHEMILUMIN THYROID STIMULA	THYROID NE (T3): SERUM 0.1 IESCENT MICROPARTICLE IMMUNOASSAY 8.0 SERUM 8.0 IESCENT MICROPARTICLE IMMUNOASSAY 8.0	FUNCTIO 781	DN TEST: TOTAL ng/mL	
THYROXINE (T4): 5 by CMIA (CHEMILUMIN THYROID STIMULA	THYROID NE (T3): SERUM 0.1 IESCENT MICROPARTICLE IMMUNOASSAY) 8.0 SERUM 8.0 IESCENT MICROPARTICLE IMMUNOASSAY) 3.1 ATING HORMONE (TSH): SERUM 3.1 IESCENT MICROPARTICLE IMMUNOASSAY) 3.1	FUNCTIO 781 04	DN TEST: TOTAL ng/mL µgm/dL	4.87 - 12.60

CLINICAL CONDITION	Т3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

LIMITATIONS:-

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.

2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).

3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.

4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTH	YRONINE (T3)	THYROX	INE (T4)	THYROID STIMU	LATING HORMONE (TSH)
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range (µIU/mL)
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 - 17.04	3 Days – 6 Months	0.70 - 8.40
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 - 16.16	6 – 12 Months	0.70 - 7.00





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 15 of 2





	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologis		(Pathology)
NAME	: Mrs. HARPREET KAUR		
AGE/ GENDER	: 54 YRS/FEMALE	PATIENT ID	: 1679891
COLLECTED BY	: SURJESH	REG. NO./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	REGISTRATION DATE	: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296	COLLECTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 23/Nov/2024 12:29PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name			Value	Unit	t	Biological Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87-13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
	RECON	MMENDATIONS OF TSH L	EVELS DURING PRE	GNANCY (µIU/mL)		
	1st Trimester			0.10 - 2.50		
	2nd Trimester			0.20 - 3.00		
	3rd Trimester			0.30 - 4.10		

INCREASED TSH LEVELS:

1.Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3. Hashimotos thyroiditis

4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.

5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

1.Toxic multi-nodular goiter & Thyroiditis.

2. Over replacement of thyroid hormone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4. Secondary pituitary or hypothalamic hypothyroidism

5. Acute psychiatric illness

6.Severe dehydration.

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



KOS Diagnostic Lab (A Unit of KOS Healthcare)

		hopra & Microbiology) onsultant Pathologis		(Pathology)
NAME AGE/ GENDER COLLECTED BY REFERRED BY BARCODE NO. CLIENT CODE.	: Mrs. HARPREET KAUR : 54 YRS/FEMALE : SURJESH : CENTRAL PHOENIX CLUB : 01521296 : KOS DIAGNOSTIC LAB		COLLECTION DATE REPORTING DATE	: 1679891 : 012411230022 : 23/Nov/2024 09:56 AM : 23/Nov/2024 09:57AM : 23/Nov/2024 11:35AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAI), AMBALA CANTT Value	Unit	Biological Reference interval
		value	UIII	biological Melerence interval
	DROXY VITAMIN D3): SERU ESCENCE IMMUNOASSAY)	M 32.137	ng/mL	DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
	CIENT:	< 20	n	g/mL
	ICIENT:	21 - 29		g/mL
	D RANGE:	30 - 100		g/mL
issue and tightly bou 3.Vitamin D plays a p phosphate reabsorpti 4.Severe deficiency m DECREASED: 1.Lack of sunshine exi 2.Inadequate intake, 3.Depressed Hepatic 4.Secondary to advan 5.Osteoporosis and So 5.Enzyme Inducing dr NCREASED: 1. Hypervitaminosis D gevere hypercalcemia 2.AUTION : Replaceme hypervitaminosis D	Ind by a transport protein whi rimary role in the maintenanc on, skeletal calcium depositio hay lead to failure to mineraliz posure. malabsorption (celiac disease Vitamin D 25- hydroxylase act ced Liver disease econdary Hyperparathroidism ugs: anti-epileptic drugs like p b is Rare, and is seen only after and hyperphophatemia. In therapy in deficient individu	le in circulation. e of calcium homen, calcium mobilizz e newly formed os) ivity (Mild to Moderate henytoin, phenoba prolonged exposu	ostatis. It promotes calciur ation, mainly regulated by teoid in bone, resulting in i e deficiency) irbital and carbamazepine, re to extremely high doses ored by periodic assessmer	port form of Vitamin D, being stored in adipose m absorption, renal calcium absorption and parathyroid harmone (PTH). rickets in children and osteomalacia in adults. that increases Vitamin D metabolism. of Vitamin D. When it occurs, it can result in nt of Vitamin D levels in order to prevent ciency due to excess of melanin pigment which
interefere with Vitamiı	n D absorption.			





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







		Chopra y & Microbiology) Consultant Pathologist	Dr. Yugam MD (I CEO & Consultant F	Pathology)
NAME	: Mrs. HARPREET KAUR			
AGE/ GENDER	: 54 YRS/FEMALE	PATIE	NT ID	: 1679891
COLLECTED BY	: SURJESH	REG. N	0./LAB NO.	: 012411230022
REFERRED BY	: CENTRAL PHOENIX CLUB			: 23/Nov/2024 09:56 AM
BARCODE NO.	: 01521296		CTION DATE	: 23/Nov/2024 09:57AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 23/Nov/2024 12:29PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	AD, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
by CMIA (CHEMILUMIN	BALAMIN: SERUM	VITAMIN B12/CO 338 POASSAY)	BALAMIN pg/mL	190.0 - 890.0
INTERPRETATION:-		338 IOASSAY)		
by CMIA (CHEMILUMIN INTERPRETATION:-	IESCENT MICROPARTICLE IMMUN	338 OASSAY)	pg/mL DECREASED VITAMIN	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 hin C gen	338 DASSAY) 1.Pregnancy 2.DRUGS:Aspirin	pg/mL DECREASED VITAMIN	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A	338 DOASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti	pg/mL DECREASED VITAMIN n, Anti-convulsants, on	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan 4.Hepatocellular in	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 3.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones is	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 hin C gen hin A jury e disorder	338 OASSAY) 2.DRUGS:Aspiri 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye	pg/mL	<u>B12</u>
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob	VESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury re disorder amin) is necessary for hemato tained only from animal prote	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa	pg/mL	B12 Colchicine ion.
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v	VESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury re disorder amin) is necessary for hemato tained only from animal prote	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa	pg/mL	B12 Colchicine
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted.	VESCENT MICROPARTICLE IMMUN SED VITAMIN B12 hin C gen hin A jury te disorder tamin) is necessary for hemato tained only from animal prote itamin B12 stores very econor	338 POASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror pins and requires intrinsic fa mically, reabsorbing vitamin	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones is eloma hal function. actor (IF) for absorpt B12 from the ileum	B12 Colchicine Colchicine Image: state of the liver;
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted. 4.Vitamin B12 deficié ileal resection, small	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury re disorder amin) is necessary for hemato tained only from animal prote itamin B12 stores very econor ency may be due to lack of IF s l intestinal diseases).	338 DOASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror pins and requires intrinsic fa mically, reabsorbing vitamin secretion by gastric mucosa	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones is iloma hal function. actor (IF) for absorpt B12 from the ileum (eg, gastrectomy, ga	B12 Colchicine Colchicine ion. and returning it to the liver; very little is stric atrophy) or intestinal malabsorption (et
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted. 4.Vitamin B12 deficié lleal resection, small 5.Vitamin B12 deficié	IESCENT MICROPARTICLE IMMUN SED VITAMIN B12 nin C gen nin A jury re disorder tained only from animal prote itamin B12 stores very econor ency may be due to lack of IF s i intestinal diseases). ency frequently causes macro	338 OASSAY) 1.Pregnancy 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa mically, reabsorbing vitamin secretion by gastric mucosa cytic anemia, glossitis, perip	pg/mL DECREASED VITAMIN n, Anti-convulsants, v on e Harmones is cloma hal function. B12 from the ileum (eg, gastrectomy, ga bheral neuropathy, w	B12 Colchicine Colchicine ion. and returning it to the liver; very little is stric atrophy) or intestinal malabsorption (en veakness, hyperreflexia, ataxia, loss of
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted. 4.Vitamin B12 deficié ileal resection, small 5.Vitamin B12 deficié proprioception, poor	SED VITAMIN B12 nin C gen nin A jury re disorder tained only from animal protection itamin B12 stores very econor ency may be due to lack of IF so i intestinal diseases). ency frequently causes macrous coordination, and affective b	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspirit 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa mically, reabsorbing vitamin secretion by gastric mucosa cytic anemia, glossitis, perip behavioral changes. These m	pg/mL DECREASED VITAMIN n, Anti-convulsants, v on e Harmones is cloma hal function. B12 from the ileum (eg, gastrectomy, ga bheral neuropathy, w	B12 Colchicine Colchicine ion. and returning it to the liver; very little is stric atrophy) or intestinal malabsorption (et
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted. 4.Vitamin B12 deficié ileal resection, small 5.Vitamin B12 deficié proprioception, poor the neurologic defec 6.Serum methylmalo	VESCENT MICROPARTICLE IMMUN SED VITAMIN B12 min C gen min A jury e disorder tamin) is necessary for hematu tained only from animal protective itamin B12 stores very econor ency may be due to lack of IF sc intestinal diseases). ency frequently causes macro- coordination, and affective b ts without macrocytic anemia. nic acid and homocysteine leve	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspiri 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa mically, reabsorbing vitamin secretion by gastric mucosa cytic anemia, glossitis, perip pehavioral changes. These milest vels are also elevated in vita	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones is eloma hal function. actor (IF) for absorpti B12 from the ileum (eg, gastrectomy, gas oberal neuropathy, wanifestations may ocomin B12 deficiency s	B12 Colchicine Colchicine ion. and returning it to the liver; very little is stric atrophy) or intestinal malabsorption (excerning any combination; many patients have veakness, hyperreflexia, ataxia, loss of cour in any combination; many patients have states.
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Vitan 4.Hepatocellular in 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (cobal 2.In humans, it is ob 3.The body uses its v excreted. 4.Vitamin B12 deficié leal resection, small 5.Vitamin B12 deficié proprioception, poor the neurologic defec 5.Serum methylmalo 7.Follow-up testing f	VESCENT MICROPARTICLE IMMUN SED VITAMIN B12 min C gen min A jury e disorder tamin) is necessary for hematu tained only from animal protective itamin B12 stores very econor ency may be due to lack of IF st intestinal diseases). ency frequently causes macro- coordination, and affective b ts without macrocytic anemia. nic acid and homocysteine levor or antibodies to intrinsic factor	338 OASSAY) 1.Pregnancy 2.DRUGS:Aspiri 3.Ethanol Igesti 4. Contraceptive 5.Haemodialysi 6. Multiple Mye opoiesis and normal neuror eins and requires intrinsic fa mically, reabsorbing vitamin secretion by gastric mucosa cytic anemia, glossitis, perip pehavioral changes. These m vels are also elevated in vita or (IF) is recommended to id	pg/mL DECREASED VITAMIN n, Anti-convulsants, i on e Harmones is eloma hal function. hal function. hal function. B12 from the ileum (eg, gastrectomy, gas oberal neuropathy, wanifestations may oc min B12 deficiency s lentify this potential	B12 Colchicine Colchicine ion. and returning it to the liver; very little is stric atrophy) or intestinal malabsorption (express, hyperreflexia, ataxia, loss of ccur in any combination; many patients have

NOTE: A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 does not rule out tissue deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







	Dr. Vinay Chopra MD (Pathology & Microbiolo Chairman & Consultant Path	Microbiology)		(Pathology) Pathologist	
NAME : Mrs. HA	RPREET KAUR				
AGE/ GENDER : 54 YRS/H	FEMALE	PATIENT I	D	: 1679891	
COLLECTED BY : SURJESH	[REG. NO./L	AB NO.	: 012411230022	
REFERRED BY : CENTRA	: CENTRAL PHOENIX CLUB (AMBALA C		FION DATE	: 23/Nov/2024 09:56 AM	
BARCODE NO. : 0152129	06	COLLECTIO	ON DATE	: 23/Nov/2024 09:57AM	
	GNOSTIC LAB	REPORTIN	G DATE	: 23/Nov/2024 11:50AM	
CLIENT ADDRESS : 6349/1,	NICHOLSON ROAD, AMBALA C	ANTT			
Test Name	Valu	le	Unit	Biological Reference interval	
	CLINI URINE ROUTINE &	CAL PATHOI MICROSCOPI		ATION	
PHYSICAL EXAMINATION					
QUANTITY RECIEVED by DIP STICK/REFLECTANCE SPEC	10		ml		
COLOUR		BER YELLOW		PALE YELLOW	
by DIP STICK/REFLECTANCE SPEC		'A D		CLEAR	
TRANSPARANCY by DIP STICK/REFLECTANCE SPEC	CLE TROPHOTOMETRY	.AK		CLEAR	
SPECIFIC GRAVITY	1.0	1		1.002 - 1.030	
by DIP STICK/REFLECTANCE SPEC CHEMICAL EXAMINATION	TROPHOTOMETRY				
REACTION	ACI	DIC			
by DIP STICK/REFLECTANCE SPEC PROTEIN		Negative		NEGATIVE (-ve)	
by DIP STICK/REFLECTANCE SPEC	TROPHOTOMETRY				
SUGAR by DIP STICK/REFLECTANCE SPEC		Negative		NEGATIVE (-ve)	
pH	6.5			5.0 - 7.5	
by DIP STICK/REFLECTANCE SPEC BILIRUBIN		ative		NEGATIVE (-ve)	
by DIP STICK/REFLECTANCE SPEC	TROPHOTOMETRY				
NITRITE by DIP STICK/REFLECTANCE SPEC		ative		NEGATIVE (-ve)	
UROBILINOGEN by DIP STICK/REFLECTANCE SPEC	Nor	mal	EU/dL	0.2 - 1.0	
KETONE BODIES by DIP STICK/REFLECTANCE SPEC	Neg	ative		NEGATIVE (-ve)	
BLOOD	Neg	ative		NEGATIVE (-ve)	
by DIP STICK/REFLECTANCE SPEC ASCORBIC ACID by DIP STICK/REFLECTANCE SPEC	NEC TROPHOTOMETRY	GATIVE (-ve)		NEGATIVE (-ve)	
MICROSCOPIC EXAMINATIO			/**= =		
RED BLOOD CELLS (RBCs)	NEO	GATIVE (-ve)	/HPF	0 - 3	



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt - 133 001, Haryana

 KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com







EXCELLENCE IN HEALTHCARE & DIAGNOSTICS

Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist CEO : Mrs. HARPREET KAUR

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME	: Mrs. HARPREET KAUR				
AGE/ GENDER	: 54 YRS/FEMALE : SURJESH : CENTRAL PHOENIX CLUB (AMBALA CANTT) : 01521296 : KOS DIAGNOSTIC LAB		PATIENT ID	: 1679891 : 012411230022 : 23/Nov/2024 09:56 AM : 23/Nov/2024 09:57AM : 23/Nov/2024 11:50AM	
COLLECTED BY			REG. NO./LAB NO.		
REFERRED BY			REGISTRATION DATE		
BARCODE NO.			COLLECTION DATE		
CLIENT CODE.			REPORTING DATE		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AI	MBALA CANTT	2		
Test Name		Value	Unit	Biological Reference interval	
by MICROSCOPY ON C	CENTRIFUGED URINARY SEDIMENT				
PUS CELLS by MICROSCOPY ON C	CENTRIFUGED URINARY SEDIMENT	1-3	/HPF	0 - 5	

by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT				
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	5-7	/HPF	ABSENT	
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)	
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)	
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)	
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)	
TRICHOMONAS VAGINALIS (PROTOZOA)	ABSENT		ABSENT	

** End Of Report ***



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

UR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

